Royalty Pharma Becomes an Investor in ApiJect
Posted on 05/20/2022
ApiJect Holdings, Inc., the parent company of ApiJect Systems, Corporation, a medical technology public-benefit corporation transforming the fill and finish and delivery of injectable vaccines and medicines, announced that it had completed a $111 million private round of investment. This is company set up to provide safe, cheap prefilled syringes to developing countries.
This investment round values ApiJect at approximately $300 million. The new round was led by Royalty Pharma and Jefferies Financial Group (NYSE: JEF), which acquired a revenue interest in addition to equity. Jefferies and ApiJect’s other lenders also converted all of their debt into ApiJect equity, such that following this transaction, ApiJect has no debt on its balance sheet.
ApiJect Systems, Corporation is a public-benefit medical technology company. In March 2020, Jefferies Financial Group invested US$ 10 million in ApiJect.
